BofA raised the firm’s price target on Cytokinetics (CYTK) to $52 from $45 and keeps a Neutral rating on the shares. The ESC conference “was a win for the company,” headlined by MAPLE trial data for aficamten, the analyst tells investors. However, while the firm doesn’t disagree with the view that aficamten has “solid clinical value,” practical headwinds are already slowing uptake in advanced patients for drugs in its class, so the firm says it is “challenging for us to forecast much early-line use.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Buy Rating Justified for Cytokinetics Due to Aficamten’s Advantages in HCM Treatment
- Cytokinetics price target raised to $80 from $60 at Evercore ISI
- ‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results
- Cytokinetics Highlights Aficamten Data at ESC Congress
- Cytokinetics price target raised to $71 from $53 at Barclays